elbion partners with Oakwood Laboratories for sustained release Naltrexone treatment for alcohol dependence

Leuven, Belgium, 15 January 2008 - elbion NV, a European specialty pharmaceutical company with a focus on neurology and immunology, today announced that it has entered a collaboration agreement with Oakwood Laboratories, L.L.C for manufacturing of its Naltrexone Depot sustained release product for alcohol dependence.

Oakwood Laboratories of Oakwood Village (near Cleveland), Ohio, USA is a privately held company specializing in the development and manufacture of controlled release injectable pharmaceutical formulations. elbion ´s Naltrexone Depot is designed as a monthly intramuscular injection. elbion believes the formulation has significant advantages over conventional naltrexone products, for which treatment compliance is a major limiting factor. Previous clinical trials with Naltrexone Depot have shown encouraging results with a trend towards greater levels of abstinence for patients receiving treatment compared to those on placebo.

More info on elbion's website or on the press release